Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
J. Vansteenkiste (Leuven, Belgium). Combined modality treatment for NSCLC. Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Modern radiotherapy as a curative treatment modality for stage III NSCLC Source: International Congress 2019 – Locally advanced non-small cell lung cancer in 2019: novel diagnostic and therapeutic strategies to tackle complex stage III disease Year: 2019 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 Possibilities of palliative combined therapy for extensive nonsmall cells lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 378s Year: 2001 Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Use of 2nd-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Successful targeted therapy of advanced lung cancer Source: Annual Congress 2013 –Grand Round on diagnostic and therapeutic challenges in thoracic oncology: an interactive session Year: 2013 Preoperative endobronchial photodynamic therapy improves surgical radicalism for locally advanced NSCLC Source: Annual Congress 2012 - From the laser through the stent to the valve: the broad spectrum of interventional pneumology Year: 2012 Role of adjuvant/neoadjuvant treatment in stage I NSCLC Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC) Year: 2014 Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Iodine-125 seed brachytherapy combined with pembrolizumab for advanced non-small-cell lung cancer after failure of first-line chemotherapy. Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Definitive radiation therapy for elderly patients with stage III NSCLC not candidates for combined chemoradiation Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 The 7-year results of the surgical treatment of non-small cell lung cancer (NSCLC) patients and the influence of neoadjuvant treatment Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007 Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection? Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications Year: 2019 Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020